What is in the GLOW blend?

Three compounds in one vial: GHK-Cu, a copper-binding tripeptide; BPC-157, a pentadecapeptide originally identified in gastric juice; and TB-500, a synthetic fragment of thymosin beta 4. Compositions vary between presentations, so the calculator takes the milligram amounts from your label rather than assuming them.

Why is the GHK-Cu amount so much larger than the others?

Because the compounds are not dosed on the same scale. GHK-Cu targets sit in the milligram range while the other two sit lower, so a blend intended to deliver all three at once has to load more of it. The consequence is that the vial’s ratio, not your intent, decides how the three land relative to their own targets. The titration table shows exactly where each one falls.

How does the calculator pick one draw for three compounds?

It takes the largest volume at which none of the three passes its own upper bound in the engine dose table, then reports what that draw delivers to each and whether it is on, under or over that component’s target. The page names the component that set the limit. A static chart prints one volume and leaves this unresolved.

What is the difference between GLOW and KLOW?

KLOW is the same three compounds plus KPV, a tripeptide fragment of alpha-MSH. Adding a fourth component to a fixed vial does not change the arithmetic, but it does add another target and another ceiling that the single shared draw has to respect. There is a separate KLOW calculator on this site.

Does body weight change the doses?

Only for TB-500. The engine catalog flags it weight sensitive and carries a per-kilogram factor. GHK-Cu and BPC-157 carry no such factor and the dose calculator applies no generic weight scaling, so the tool leaves their targets alone instead of scaling all three by mass.

Do the three components want the same cycle length?

Not always, and a shared vial cannot resolve that. The supplies table takes the shortest on-period among the components and says which one set it, because that is the constraint a single vial imposes. The component reference table shows each compound’s own on and off weeks so the disagreement is visible rather than averaged away.

Is copper worth watching on a copper peptide?

It is a reasonable thing to raise with a clinician, particularly on a longer run, and it is one of the reasons a protocol has a monitoring plan rather than just a dose. The Klarovel engine attaches monitoring to a protocol based on the compounds it selects. This page is the arithmetic layer, not the monitoring layer.

How much bacteriostatic water should I use?

Enough that your draw sits in a readable part of the syringe. With a lopsided blend a small draw can carry a large amount of the dominant component, so a more dilute mix often gives better resolution. Change the water volume and every table on the page recomputes.

Is this calculator free?

Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.

Does Klarovel sell this blend?

No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel. This page exists because the arithmetic of a fixed-ratio vial is genuinely hard to do in your head, not to move a product.

Is this medical advice?

No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

GLOW blend calculator

GLOW is GHK-Cu, BPC-157 and TB-500 co-mixed in one vial, and the ratio is lopsided: the copper peptide dominates the vial by mass. One draw volume has to serve all three, so knowing what each one actually receives is the whole question.

Set your vial composition, water volume, experience level and body weight. The per-component breakdown, the three-phase titration table and the supplies plan all recompute. Every dose figure is read from the Klarovel engine’s dose table, never typed into the page.

Vial composition

Vial contents, not doses. Confirm against the label on the vial in front of you before you mix.

Bacteriostatic water added

Experience with injectable peptides

Body weight

Age 65 or over

Standard phase, single shared draw

9.0 units

0.09 ml on a 100-unit insulin syringe

GHK-Cu

on target

1.5 mg

target 1.5 mg, ceiling 2 mg

BPC-157

on target

300 mcg

target 300 mcg, ceiling 500 mcg

TB-500 (Thymosin Beta-4)

under target

0.3 mg

target 2.4 mg, ceiling 2.5 mg

The draw is set by GHK-Cu, which reaches its target first. Every other component is read off the same draw because a blend has one ratio.

Per-component breakdown at every draw volume

What each draw volume actually delivers per component at 3 ml of bacteriostatic water and the vial composition selected above. These are mathematical breakdowns of the vial, not dose recommendations. The targets and ceilings are in the titration table below.

Per-component amount delivered at each insulin syringe draw volume
Draw	Volume	GHK-Cu	BPC-157	TB-500 (Thymosin Beta-4)
2 units	0.02 ml	0.333 mg	66.7 mcg	0.067 mg
4 units	0.04 ml	0.667 mg	133.3 mcg	0.133 mg
5 units	0.05 ml	0.833 mg	166.7 mcg	0.167 mg
6 units	0.06 ml	1 mg	200 mcg	0.2 mg
8 units	0.08 ml	1.333 mg	266.7 mcg	0.267 mg
10 units	0.1 ml	1.667 mg	333.3 mcg	0.333 mg
12 units	0.12 ml	2 mg	400 mcg	0.4 mg
15 units	0.15 ml	2.5 mg	500 mcg	0.5 mg
20 units	0.2 ml	3.333 mg	666.7 mcg	0.667 mg
25 units	0.25 ml	4.167 mg	833.3 mcg	0.833 mg
30 units	0.3 ml	5 mg	1000 mcg	1 mg
40 units	0.4 ml	6.667 mg	1333.3 mcg	1.333 mg
50 units	0.5 ml	8.333 mg	1666.7 mcg	1.667 mg

Arithmetic over the vial composition and your water volume. The display unit per component is the unit that component's row declares in the engine dose table.

Phase by phase titration

Three phases, in the order the engine escalates a dose: opening, standard, then upper. Every figure below is the beginner row of the engine dose table for that component, after the modifiers your inputs trigger. Change experience level, weight or age above and the whole table recomputes.

Phase 1, opening dose

draw 6.0 units

Phase 1, opening dose per component
Component	Delivered	Target	Draw for target	Ceiling
GHK-Cu	1 mg	1 mg	6.0 units	2 mg
BPC-157	200 mcg	250 mcg	7.5 units	500 mcg
TB-500 (Thymosin Beta-4)	0.2 mg	2.4 mg	72.0 units	2.5 mg

The components' own targets are reached 12x apart in draw volume, so one draw cannot satisfy them all. BPC-157, TB-500 (Thymosin Beta-4) land under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.

TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.

Phase 2, standard dose

draw 9.0 units

Phase 2, standard dose per component
Component	Delivered	Target	Draw for target	Ceiling
GHK-Cu	1.5 mg	1.5 mg	9.0 units	2 mg
BPC-157	300 mcg	300 mcg	9.0 units	500 mcg
TB-500 (Thymosin Beta-4)	0.3 mg	2.4 mg	72.0 units	2.5 mg

The components' own targets are reached 8x apart in draw volume, so one draw cannot satisfy them all. TB-500 (Thymosin Beta-4) lands under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.

TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.

Phase 3, upper dose

draw 12.0 units

Phase 3, upper dose per component
Component	Delivered	Target	Draw for target	Ceiling
GHK-Cu	2 mg	2 mg	12.0 units	2 mg
BPC-157	400 mcg	400 mcg	12.0 units	500 mcg
TB-500 (Thymosin Beta-4)	0.4 mg	2.4 mg	72.0 units	2.5 mg

The components' own targets are reached 6x apart in draw volume, so one draw cannot satisfy them all. TB-500 (Thymosin Beta-4) lands under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.

TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.

Targets, upper bounds and ceilings read from dose_protocols, the engine's dose table. Weight scaling applies only where PEPTIDE_CATALOG flags a component weight sensitive. The 0.75x age reduction is the engine's own contraindication rule for age 65 and over.

What your body weight does, and does not, change

Weight sensitive: TB-500 (Thymosin Beta-4) at 0.03 mg/kg. The engine catalog carries a per-kilogram factor for this component, so the weight you entered sets the target directly and is then held inside the beginner ceiling.

Not weight sensitive: GHK-Cu, BPC-157. The catalog does not flag these components weight sensitive and the dose calculator applies no weight scaling of its own, so changing the weight field does not move their target. Scaling every compound by body mass would be an invention, so the tool does not do it.

Supplies for one cycle

One on-cycle runs 8 weeks because that is the shortest on-period among the components, set by GHK-Cu. A single vial cannot be cycled per component, so the shortest on-period governs, followed by 8 weeks off.

Administrations per week

Options come from the components' own frequency strings: GHK-Cu is once daily, BPC-157 is once to twice daily, TB-500 (Thymosin Beta-4) is twice weekly. Where those disagree there is no single correct value, so the default is the most conservative one the data supports.

Bacteriostatic water bottle size

Supplies required for one on-cycle
Cycle length	8 weeks
Administrations per week	2
Total administrations	16
Vials	1
Insulin syringes	16 (30-unit holds the draw)
Bacteriostatic water	3 ml, 1 bottle of 10 ml

Cycle length from PEPTIDE_CATALOG cycling data. Administrations per week derived from the frequency string on each component's dose row. Vial and syringe counts are arithmetic over your draw volume and water volume.

The components' sourced frequencies do not overlap: GHK-Cu is once daily, BPC-157 is once to twice daily, TB-500 (Thymosin Beta-4) is twice weekly. A single vial forces one schedule, so no frequency satisfies every component's row. That is a real limitation of a fixed-ratio blend and the reason a protocol would run these as separate vials.

Component reference

Route, timing, frequency and cycling per component, read from the engine catalog.

Per-component administration and cycling reference
Component	Route	Timing	Frequency	Cycle	Loading phase
GHK-Cu	subcutaneous	Any time	once daily	8 on / 8 off	None
BPC-157	subcutaneous	Any time	once to twice daily	12 on / 4 off	None
TB-500 (Thymosin Beta-4)	subcutaneous	Any time	twice weekly	12 on / 4 off	4 weeks at 2x

Route, timing and cycling from PEPTIDE_CATALOG. Frequency from the beginner row of dose_protocols.

What a fixed blend cannot do, stated plainly

A blend is one ratio in one vial. There is exactly one draw volume, and it has to serve every component at once. When the ratio does not match the ratio of the components' own targets, something has to give: either a component lands under its target, or another is pushed toward its ceiling. The table above says which, for your inputs, rather than printing a single volume and leaving it unresolved.

Contraindications are the second limit. A protocol can drop one compound and keep the rest. A blend cannot, because the compounds share a vial. If a health condition rules out one component, it rules out the vial.

A Klarovel protocol is built from your health data. Blood work is optional and sharpens the result, but it never gates it. The engine resolves contraindications, sets the dose envelope by experience level, removes incompatible pairs and sets the cycling schedule. That is the difference between a calculator and a protocol.

Save your reconstitution. Get the protocol it belongs in.

Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.

Questions

What is in the GLOW blend?: Three compounds in one vial: GHK-Cu, a copper-binding tripeptide; BPC-157, a pentadecapeptide originally identified in gastric juice; and TB-500, a synthetic fragment of thymosin beta 4. Compositions vary between presentations, so the calculator takes the milligram amounts from your label rather than assuming them.
Why is the GHK-Cu amount so much larger than the others?: Because the compounds are not dosed on the same scale. GHK-Cu targets sit in the milligram range while the other two sit lower, so a blend intended to deliver all three at once has to load more of it. The consequence is that the vial’s ratio, not your intent, decides how the three land relative to their own targets. The titration table shows exactly where each one falls.
How does the calculator pick one draw for three compounds?: It takes the largest volume at which none of the three passes its own upper bound in the engine dose table, then reports what that draw delivers to each and whether it is on, under or over that component’s target. The page names the component that set the limit. A static chart prints one volume and leaves this unresolved.
What is the difference between GLOW and KLOW?: KLOW is the same three compounds plus KPV, a tripeptide fragment of alpha-MSH. Adding a fourth component to a fixed vial does not change the arithmetic, but it does add another target and another ceiling that the single shared draw has to respect. There is a separate KLOW calculator on this site.
Does body weight change the doses?: Only for TB-500. The engine catalog flags it weight sensitive and carries a per-kilogram factor. GHK-Cu and BPC-157 carry no such factor and the dose calculator applies no generic weight scaling, so the tool leaves their targets alone instead of scaling all three by mass.
Do the three components want the same cycle length?: Not always, and a shared vial cannot resolve that. The supplies table takes the shortest on-period among the components and says which one set it, because that is the constraint a single vial imposes. The component reference table shows each compound’s own on and off weeks so the disagreement is visible rather than averaged away.
Is copper worth watching on a copper peptide?: It is a reasonable thing to raise with a clinician, particularly on a longer run, and it is one of the reasons a protocol has a monitoring plan rather than just a dose. The Klarovel engine attaches monitoring to a protocol based on the compounds it selects. This page is the arithmetic layer, not the monitoring layer.
How much bacteriostatic water should I use?: Enough that your draw sits in a readable part of the syringe. With a lopsided blend a small draw can carry a large amount of the dominant component, so a more dilute mix often gives better resolution. Change the water volume and every table on the page recomputes.
Is this calculator free?: Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
Does Klarovel sell this blend?: No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel. This page exists because the arithmetic of a fixed-ratio vial is genuinely hard to do in your head, not to move a product.
Is this medical advice?: No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Other blend calculators

Same engine, different vial. Pick the page that matches what you actually have in front of you: the component list and the ratio change the arithmetic completely.

References

These papers cover the mechanism and clinical context of GHK-Cu, BPC-157 and thymosin beta 4, the parent protein TB-500 is a fragment of.

The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.

24 references, every identifier resolved against NCBI on 2026-07-30. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query).

1.Pickart L et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018. PMID 29986520 PMC6073405
2.Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMID 26236730 PMC4508379
3.Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev 2012. PMID 22666519 PMC3359723
4.Dou Y et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther 2020. PMID 35083444 PMC8789089
5.Fu SC et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res 2015. PMID 25731775
6.Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res 2009. PMID 19319546
7.Pickart L et al. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008. PMID 18644225
8.Wang X et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen 2017. PMID 28370978
9.Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 2011. PMID 21030672
10.Seiwerth S et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol 2021. PMID 34267654 PMC8275860
11.Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019. PMID 30915550
12.Józwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel) 2025. PMID 40005999 PMC11859134
13.Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949 PMC12313605
14.Lee E et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PMID 40131143
15.McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PMID 40789979 PMC12446177
16.Sikiric P et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel) 2024. PMID 38675421 PMC11053547
17.Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012. PMID 22074294
18.Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm 2016. PMID 27450738
19.Pipes GT et al. Cardioprotection by Thymosin Beta 4. Vitam Horm 2016. PMID 27450736
20.Smart N et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann N Y Acad Sci 2007. PMID 17495252
21.Zhang Y et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res 2025. PMID 41229390
22.Tan WKY et al. Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations. Expert Opin Biol Ther 2018. PMID 29502471
23.Nachmias VT et al. Small actin-binding proteins: the beta-thymosin family. Curr Opin Cell Biol 1993. PMID 8448031
24.Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026. PMID 41966639

Beyond the arithmetic

A protocol resolves what a blend cannot.

The Klarovel engine reads your health data, resolves contraindications, sets the dose envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.